H
Hugo M. Horlings
Researcher at Netherlands Cancer Institute
Publications - 129
Citations - 18740
Hugo M. Horlings is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 46, co-authored 106 publications receiving 15805 citations. Previous affiliations of Hugo M. Horlings include BC Cancer Agency & University of Amsterdam.
Papers
More filters
Journal ArticleDOI
Abstract PD15-07: Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes
Marte C. Liefaard,A. van der Voort,Joyce Sanders,S. Arjan Vonk,Hugo M. Horlings,Sabine Siesling,Linda de Munck,Elise van Leeuwen-Stok,M. Kleijn,Lorenza Mittempergher,Midas Kuilman,Esther H. Lips,Gabe S. Sonke +12 more
TL;DR: The results confirmed the results of a prior secondary analysis of the Aphinity trial that the benefit of adding pertuzumab to (neo)adjuvant trastuzumAB-based chemotherapy seems most pronounced in patients with a molecularly defined single-activated HER2-subtype.
Journal ArticleDOI
Predictive value of ectopic HORMAD1 tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.
Leonora W. de Boo,Jelmar Quist,Mark Opdam,Katarzyna Jóźwiak,Patrycja Gazinska,Dennis Peters,Hugo M. Horlings,Tessa G Steenbruggen,Lars C Steggink,Elisabeth G.E. de Vries,Gabe S. Sonke,Jourik A. Gietema,Andrew Tutt,Marleen Kok,Anita Grigoriadis,Sabine C. Linn +15 more
TL;DR: Tumor HORMAD1 expression is predictive for benefit of high-dose platinum-based chemotherapy with autologous stem cell support in patients with high-risk HER2-negative early breast cancer participating in an RCT.
Journal ArticleDOI
Characteristics of long-term survival in advanced stage ovarian cancer: a nationwide cohort in the Netherlands
L. Van Wagensveld,Gabe S. Sonke,Koen Kris Van de Vijver,Hugo M. Horlings,R. F. Kruitwagen,Maaike A. van der Aa +5 more
TL;DR: Characteristics of the tumor, patient and treatment play a substantial role in respect to the prognosis of advanced stage EOC, and can assist in the prediction of LTS.
Posted ContentDOI
Imprint of parity and age at first birth on the genomic landscape of subsequent breast cancer
Bastien Nguyen,David Venet,Matteo Lambertini,Christine Desmedt,Roberto Salgado,Hugo M. Horlings,Françoise Rothé,Christos Sotiriou +7 more
TL;DR: Genomic alterations of breast cancer are associated with age at first birth but not parity status alone, highlighting an unprecedented link between reproductive history and the genomic landscape of subsequent breast cancer.
Journal ArticleDOI
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer
L. Van Wagensveld,Juliette O.A.M. van Baal,M. Timmermans,Duco Gaillard,Lauri Borghuis,Seth B. Coffelt,Efraim H. Rosenberg,Christianne A. R. Lok,Hans W. Nijman,Loes F. S. Kooreman,Joyce Sanders,M. de Bruijn,Lodewyk F. A. Wessels,R. van der Wiel,Christian Rausch,Annegien Broeks,Roy F.P.M. Kruitwagen,Maaike A. van der Aa,Gabe S. Sonke,Philip C. Schouten,Koen Van de Vijver,Hugo M. Horlings +21 more
TL;DR: In this paper , the tumor microenvironment and genetic profiles of high grade serous ovarian carcinoma (HGSOC) were assessed and their associations with survival were found. But the authors did not consider the effect of the tumor's genetic characteristics on the tissue surrounding the tumor.